Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:ASBP NASDAQ:PMN NASDAQ:TTNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.40-3.1%$3.22$7.96▼$24.15$22.19M0.6315,685 shs215,470 shsASBPAspire Biopharma$0.43+3.1%$0.45$0.22▼$15.80$20.80M0.831.59 million shs615,844 shsPMNPromis Neurosciences$0.41-4.3%$0.59$0.38▼$1.59$22.23M-0.053.18 million shs432,079 shsTTNPTitan Pharmaceuticals$4.21$4.40$3.03▼$5.76$5.60M1.4184,502 shs3,917 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-3.08%+18.60%+75.30%+76.71%-75.44%ASBPAspire Biopharma+3.10%-2.76%-20.71%+80.72%+43,299,900.00%PMNPromis Neurosciences-4.31%-3.18%-23.40%-15.36%-66.63%TTNPTitan Pharmaceuticals+0.38%-3.79%-12.82%-3.44%-20.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.40-3.1%$3.22$7.96▼$24.15$22.19M0.6315,685 shs215,470 shsASBPAspire Biopharma$0.43+3.1%$0.45$0.22▼$15.80$20.80M0.831.59 million shs615,844 shsPMNPromis Neurosciences$0.41-4.3%$0.59$0.38▼$1.59$22.23M-0.053.18 million shs432,079 shsTTNPTitan Pharmaceuticals$4.21$4.40$3.03▼$5.76$5.60M1.4184,502 shs3,917 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-3.08%+18.60%+75.30%+76.71%-75.44%ASBPAspire Biopharma+3.10%-2.76%-20.71%+80.72%+43,299,900.00%PMNPromis Neurosciences-4.31%-3.18%-23.40%-15.36%-66.63%TTNPTitan Pharmaceuticals+0.38%-3.79%-12.82%-3.44%-20.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AASBPAspire Biopharma 0.00N/AN/AN/APMNPromis Neurosciences 3.00Buy$4.33955.62% UpsideTTNPTitan Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TTNP, ALVR, ASBP, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025PMNPromis NeurosciencesLeede FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy7/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.007/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/A$2.67 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)ASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-737.96%N/APMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)TTNPTitan Pharmaceuticals-$4.71M-$2.95N/A∞N/AN/A-108.60%-95.64%N/ALatest TTNP, ALVR, ASBP, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TTNPTitan PharmaceuticalsN/A-$0.65N/A-$0.65N/AN/A8/13/2025Q2 2025ASBPAspire BiopharmaN/A-$0.04N/A-$0.04N/AN/A8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AASBPAspire BiopharmaN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78ASBPAspire BiopharmaN/A0.090.09PMNPromis NeurosciencesN/A0.970.97TTNPTitan PharmaceuticalsN/A11.6011.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%ASBPAspire Biopharma19.17%PMNPromis Neurosciences50.13%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%ASBPAspire Biopharma48.00%PMNPromis Neurosciences6.11%TTNPTitan Pharmaceuticals0.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/APMNPromis Neurosciences551.81 million48.64 millionNot OptionableTTNPTitan Pharmaceuticals101.33 million1.32 millionOptionableTTNP, ALVR, ASBP, and PMN HeadlinesRecent News About These CompaniesTitan Pharmaceuticals Approves Merger with Black TitanAugust 26, 2025 | msn.comTITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5, 2025 | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comTitan Pharmaceuticals Inc (TTNP) - Investing.comJuly 4, 2025 | investing.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29, 2025 | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29, 2025 | nasdaq.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | finance.yahoo.comTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset ManagementJune 27, 2025 | quiverquant.comQTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | globenewswire.comtitan pharmaceuticals issues common stock following preferred stock conversionsJune 4, 2025 | investing.comTitan announces filing of registration statement for proposed combinationJune 4, 2025 | finance.yahoo.comTitan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.June 3, 2025 | quiverquant.comQTitan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.June 3, 2025 | globenewswire.comTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockApril 11, 2025 | globenewswire.comTitan Pharmaceuticals: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comTitan Pharmaceuticals receives Nasdaq notice of non-complianceNovember 27, 2024 | markets.businessinsider.comTitan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee RequirementsNovember 27, 2024 | quiverquant.comQTitan Pharmaceuticals, Inc. Announces Receipt of Notice from NasdaqNovember 27, 2024 | globenewswire.comSanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatOctober 25, 2024 | msn.comTitan Pharmaceuticals, Inc. (TTNP)October 17, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTTNP, ALVR, ASBP, and PMN Company DescriptionsAlloVir NASDAQ:ALVR$4.40 -0.14 (-3.08%) As of 09/22/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Aspire Biopharma NASDAQ:ASBP$0.43 +0.01 (+3.10%) As of 09/23/2025 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Promis Neurosciences NASDAQ:PMN$0.41 -0.02 (-4.31%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$0.41 0.00 (-1.10%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Titan Pharmaceuticals NASDAQ:TTNP$4.21 0.00 (0.00%) Closing price 09/23/2025 03:40 PM EasternExtended Trading$4.29 +0.08 (+1.88%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
